Physician profile
Jay L Steinberg
NPI 1366440950
$7,594.47
in general payments reported to CMS, 2019-2025
39 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $474 · 2021: $978 · 2022: $809 · 2023: $1,609 · 2024: $1,676 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663 · Education: $94.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.74 |
| Education | $94.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.70 | 2019-2025 | Viberzi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $773.16 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $645.30 | 2019-2025 | Xifaxan |
| Pfizer INC. | $505.37 | 2019-2025 | |
| Lilly USA, LLC | $368.49 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $308.48 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $275.38 | 2022-2023 | Dupixent |
| Daiichi Sankyo INC. | $264.04 | 2019-2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $259.39 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $237.26 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $227.80 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $225.46 | 2022-2025 | Ibsrela |
| Celgene Corporation | $212.15 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $187.66 | 2019-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $153.64 | 2024-2025 | Iqirvo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $144.80 | 2019-2022 | |
| Lundbeck LLC | $134.51 | 2023-2025 | Vyepti |
| Ironwood Pharmaceuticals, INC | $119.86 | 2021-2023 | Linzess |
| Merck Sharp & Dohme LLC | $114.42 | 2019-2023 | Dificid |
| Exact Sciences Corporation | $97.14 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $86.33 | 2020-2021 | |
| Celltrion USA INC. | $79.87 | 2024 | Zymfentra |
| Genzyme Corporation | $51.24 | 2023 | |
| Neurelis, INC. | $40.45 | 2023-2025 | Valtoco |
| Madrigal Pharmaceuticals | $37.86 | 2025 | Rezdiffra |
| Grifols USA, LLC | $31.82 | 2025 | Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.70 | 2023 | Cyltezo |
| Novo Nordisk INC | $28.58 | 2025 | Wegovy |
| Ucb, INC. | $27.55 | 2020 | |
| Alexion Pharmaceuticals, INC. | $26.30 | 2025 | Ultomiris |
| Sandoz INC. | $23.08 | 2024 | Hyrimoz |
| Orphalan INC | $21.76 | 2024 | Cuvrior |
| Medtronic, INC. | $21.03 | 2025 | Gi Genius |
| Amneal Pharmaceuticals LLC | $20.43 | 2024 | Crexont |
| Allergan, INC. | $14.53 | 2019 | |
| W. L. Gore & Associates, INC. | $13.92 | 2020 | |
| Gilead Sciences, INC. | $13.66 | 2019 | |
| Endo Pharmaceuticals INC. | $12.85 | 2019 | |
| Thd America, INC. | $12.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.